September 25, 2023
Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in France
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at...
Read More
September 14, 2023
RESI Boston 2023 – September 18th
Immunophotonics Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Boston attending the RESI Boston...
Read More
September 13, 2023
CIRSE 2023 September 9 – 13, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be at Booth F18 at the CIRSE...
Read More
July 17, 2023
Immunophotonics Announces 1st Patient Treated in Germany
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The...
Read More
June 1, 2023
Immunophotonics Announces 1st Patient Dosed in Multinational Clinical Trial in the United Kingdom
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the...
Read More
June 1, 2023
SACHS Forum and ASCO Annual Meeting in Chicago June 2 – 6, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th...
Read More
May 18, 2023
Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S.
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of...
Read More
April 20, 2023
Swiss Biotech Day 2023 April 24 & 25
Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development...
Read More
April 12, 2023
European Conference on Interventional Oncology (ECIO 2023) April 16 – 19
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European...
Read More
April 5, 2023
Indian Patent Office Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001
Immunophotonics is excited to announce that its composition-of-matter patent has been granted by the Indian Patent Office (ISA/IPEA). With this...
Read More